Agonist News and Research

RSS

Systematic analysis reveals psilocybin's impact on obsessive-compulsive behaviors

A systematic review published today in Psychedelics by Mr. James Gattuso and colleagues at the Florey Institute of Neuroscience and Mental Health synthesizes clinical and preclinical evidence on psilocybin's effects on obsessive-compulsive behaviors, revealing consistent therapeutic potential across human patients and validated animal models.

29 Oct 2025

Adequate support needed to address Canada's rising youth opioid use

Youth opioid use is increasing in Canada, as are related emergency department visits and deaths, yet governments are not providing adequate support to address this public health crisis, argue the authors of a CMAJ.

27 Oct 2025

Semaglutide protects the heart beyond weight loss, SELECT trial shows

Semaglutide lowered the risk of major adverse cardiovascular events across all body weight and waist circumference levels in people with overweight or obesity and cardiovascular disease. Early waist reduction explained only a third of this benefit, showing that semaglutide’s heart protection extends beyond fat loss.

26 Oct 2025

New insight into TRPM3 heat sensor reveals how the body detects temperature

The ability to sense heat protects the body from burns and injury. But how the body actually feels temperature has remained an elusive mystery.

24 Oct 2025

Study reveals how DKK3 triggers smooth muscle cell transformation in aortic aneurysm

Abdominal aortic aneurysm (AAA) is a life-threatening vascular disorder that primarily affects elderly males.

10 Oct 2025

GLP-1 therapeutics may have the potential to treat alcohol and drug addiction

A popular class of therapies for treating diabetes and obesity may also have the potential to treat alcohol and drug addiction, according to a new paper published in the Journal of the Endocrine Society.

9 Oct 2025

GLP-1 receptor agonists linked to altered patterns on FDG PET-CT scans

The growing use of GLP-1 receptor agonists may affect the interpretation of oncological FDG PET-CT scans, new research presented today at the 38th Annual Congress of the European Association of Nuclear Medicine (EANM'25) has revealed.

7 Oct 2025

Study finds surge in the use of weight loss drugs among bariatric surgery patients

New research findings show a significant increase in the use of weight loss drugs among patients undergoing metabolic and bariatric surgery, signaling an evolution in the management of obesity and Type 2 diabetes.

3 Oct 2025

FAU study explores how a new drug may help treat PTSD and its common companions

About 12 million adults in the United States are affected by PTSD, impacting between 4% and 8% of the adult population – and up to 30% of military personnel and veterans.

24 Sep 2025

Study provides new insights into the mechanisms of fetal membrane healing

When a pregnant woman's water breaks too early, it often leads to preterm birth, with no effective method to prevent or treat it.

23 Sep 2025

New quintuple agonist shows promise for treating obesity and type 2 diabetes

Much excitement has built in recent years on the new class of incretin drugs that include glucagon-like-peptide-1 inhibitor (single agonists such as semaglutide) and also dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonists (dual agonists such tirzepatide).

21 Sep 2025

New trial demonstrates efficacy of tirzepatide in children and adolescents with type 2 diabetes

New research shows that that the diabetes/obesity medication tirzepatide can cause clinically meaningful improvements in blood sugar control and weight loss in children and adolescents with type 2 diabetes aged 10-17 years whose diabetes and weight are inadequately controlled with an existing treatment regimen of metformin, insulin, or both.

18 Sep 2025

Daily orforglipron GLP-1 pill achieves over 11% weight loss in global obesity trial

In a phase 3 trial, once-daily oral orforglipron induced significant, dose-dependent weight loss over 72 weeks in adults with obesity but no diabetes. It also improved multiple cardiometabolic markers with a safety profile similar to other GLP-1 receptor agonists.

18 Sep 2025

A new tool in the fight against obesity: Orforglipron's substantial weight loss results

New research presented at the Annual Meeting of the European Association for the Study of Diabetes in Vienna, Austria (Sept 15-19) and simultaneously published in NEJM shows that daily treatment with the new once-daily GLP-1 agonist orforglipron results in substantial weight loss in people living with obesity that do not have type 2 diabetes.

17 Sep 2025

GLP-1 drugs found to protect against diabetic retinopathy

GLP-1 receptor agonist drugs protect against diabetic retinopathy, a common complication of diabetes that can lead to sight loss, suggests new research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria (15-19 September) and published in the journal Pharmaceutics.

17 Sep 2025

The mind-gut connection: How emotional eating affects GLP-1 drug success

GLP-1 receptor agonists like Ozempic can be a lifeline for people with diabetes - helping stabilize blood glucose and lose weight which contributes to diabetes complications. But not everyone benefits equally.

17 Sep 2025

Exercise found to reduce artery hardening after weight loss in adults with obesity

Maintaining weight loss with regular exercise rather than the glucagon-like peptide-1 receptor agonist (GLP-1RA) liraglutide, a drug used to treat type 2 diabetes and obesity, seems to reduce atherosclerosis development in adults with obesity-a leading underlying cause of cardiovascular disease.

17 Sep 2025

Agonist News and Research

Systematic analysis reveals psilocybin's impact on obsessive-compulsive behaviors

Adequate support needed to address Canada's rising youth opioid use

Semaglutide protects the heart beyond weight loss, SELECT trial shows

New insight into TRPM3 heat sensor reveals how the body detects temperature

Study reveals how DKK3 triggers smooth muscle cell transformation in aortic aneurysm

GLP-1 therapeutics may have the potential to treat alcohol and drug addiction

GLP-1 receptor agonists linked to altered patterns on FDG PET-CT scans

Study finds surge in the use of weight loss drugs among bariatric surgery patients

FAU study explores how a new drug may help treat PTSD and its common companions

Study provides new insights into the mechanisms of fetal membrane healing

New quintuple agonist shows promise for treating obesity and type 2 diabetes

New trial demonstrates efficacy of tirzepatide in children and adolescents with type 2 diabetes

Daily orforglipron GLP-1 pill achieves over 11% weight loss in global obesity trial

A new tool in the fight against obesity: Orforglipron's substantial weight loss results

GLP-1 drugs found to protect against diabetic retinopathy

The mind-gut connection: How emotional eating affects GLP-1 drug success

Exercise found to reduce artery hardening after weight loss in adults with obesity

Scientists find a smarter way to activate the immune system against cancer

Cleveland Clinic study shows lasting benefits of weight-loss surgery over GLP-1 medicines

Are GLP-1 drugs safe for women planning pregnancy?

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News